18 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Oral anticoagulants The coumarin anticoagulants, warfarin…
What factors should be considered when using LMWH to treat venous thromboembolism in patients with high body weight?
14 September 2020Treatment of venous thromboembolism (VTE) in patients with high body weight constitutes a challenge in clinical practice. Adjustments in the dose calculation may be necessary…
25 March 2020Randomised controlled trials evaluating LMWH efficacy and safety have generally excluded patients with severe renal impairment (RI). In contrast to UFH, LMWHs are primarily cleared…
Low molecular weight heparins – should prophylactic doses be used in patients with renal impairment?
23 October 2019This updated Medicines Q & A reviews the evidence available and considers when prophylactic doses of low molecular weight heparins can be used in patients…
What is the evidence for the use of Low Molecular Weight Heparins for the prophylaxis of travel-related thrombosis?
4 September 2018This Medicines Q&A evaluates the evidence for using low molecular weight heparins for the prevention of travel-related venous thromboembolism
Lactation Safety Information
Limited published evidence of safety
Small amounts in breast milk
Not absorbed from the infant’s GI tract
Used in full-term neonates from birth
20 October 2016